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Abstract Multiple myeloma is a malignant B-cell neoplasm
that involves the skeleton in approximately 80% of the
patients. With an average age of 60 years and a 5-years
survival of nearly 45% Brenner et al. (Blood 111:2516–2520,
35) the onset is to be classified as occurring still early in life
while the disease can be very aggressive and debilitating. In
the last decades, several new imaging techniques were intro-
duced. The aim of this review is to compare the different
techniques such as radiographic survey, multidetector com-
puted tomography (MDCT), whole-body magnetic resonance
imaging (WB-MRI), fluorodeoxyglucose positron emission
tomography- (FDG-PET) with or without computed tomog-
raphy (CT), and
99mTc-methoxyisobutylisonitrile (
99mTc-
MIBI) scintigraphy. We conclude that both FDG-PET in
combination with low-dose CT and whole-body MRI are
more sensitive than skeleton X-ray in screening and
diagnosing multiple myeloma. WB-MRI allows assessment
of bone marrow involvement but cannot detect bone
destruction, which might result in overstaging. Moreover,
WB-MRI is less suitable in assessing response to therapy
than FDG-PET. The combination of PET with low-dose CT
can replace the golden standard, conventional skeletal
survey. In the clinical practise, this will result in upstaging,
due to the higher sensitivity.
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Introduction
Multiple myeloma is a neoplasm of B cells which is charac-
terised by bone marrow infiltration and production of mono-
clonal immunoglobulins [1]. Multiple myeloma accounts for
approximately 10% of the hematologic malignancies and the
incidence is increasing, reaching four in every 100,000 per
year with a peak during the seventh decade of life [2].
The diagnosis is based on laboratory parameters in
combination with bone marrow biopsy or bone marrow
aspiration[3] providing information about paraproteinaemia,
bone marrow plasma cell infiltration and osteolytic bone
destruction. Lytic bone lesions are present in approximately
80% of patients with a high risk of pathological fractures,
hypercalcaemia and bone pain [1].
In staging, treatment evaluation and prognosis of patients
with multiple myeloma, detection of osteolytic bone lesions
has critical value. Even though new imaging techniques as
FDG-PET/CT or WB-MRI have been introduced to assess
extent and severity of multiple myeloma, most institutions
still use conventional radiographs to evaluate disease stage,
progression and therapy response, since this technology had
been evaluated in many studies in the past and still is
considered to be the golden standard. Moreover, in the
Durie and Salmon myeloma staging system (Table 1)
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DOI 10.1007/s00277-009-0829-0introduced in 1975 [4], the detection of bone lesions by
radiographic survey correlated with measured myeloma cell
mass. This staging system has been widely used over the
past 30 years.
Unfortunately, despite low costs and wide employment
and availability, the use of conventional radiography,
especially whole-body surveys, has several limitations.
Radiography
Conventional radiography
Conventional skeletal survey is used in the initial work-up
in patients with multiple myeloma, although the false-
negative rate (30–70%) is relatively high, leading to
significant underestimation in diagnosing and staging of
patients with multiple myeloma [5].
Diffuse bone marrow involvement, which may or may
not be associated with bone destruction, is not evaluable
using conventional radiography. Although the role of early
diagnosis and treatment of bone marrow involvement is not
yet established, lytic lesions become apparent on conven-
tional radiography when already 30–50% of the bone
mineral density is lost [6]. Early myeloma may thus not
reveal observable changes on conventional radiographs.
Moreover, osteopaenia as a result of bone marrow
infiltration by multiple myeloma as well as osteoclast-
activity induced by this disease cannot be distinguished
on conventional radiographs from more common causes
Table 1 Overview of the original Durie/Salmon staging system (A) and the Durie/Salmon PLUS staging system (B)
A: Original system B: Plus system
CRITERIA Measured myeloma cell mass in
whole body (myeloma cells in
billions/m
2)[ 35]
Classification Plus New imaging MRI and/or
FDG-PET
Stage I (low cell mass) 600 billion MGUS All negative
All of the following:
Haemoglobin value >10 g/dl
Serum calcium value normal or
<10.5 mg/dl
Bone X-ray, normal bone structure
(scale 0), or solitary bone plasma-
cytoma only
Low M-component production rates:
IgG value <5.0 g/dl
IgA value <3.0 g/dl
Urine light chain M-component on
electrophoresis <4 g/24 h
Stage II (intermediate cell mass)
Fitting neither stage I nor stage III 600–1,200 billion Stage I A [35]
(Smouldering or
indolent)
Can have single plasmacytoma
and/or limited disease on
imaging
Stage III (high cell mass) > 1,200 billion Multiple myeloma
One or more of the following:
Haemoglobin value <8.5 g/dl <5 focal lesions
Serum calcium value >12 mg/dl Stage I B [35] Mild diffuse disease
Advanced lytic bone lesions (scale 3) 5–20 focal lesions
High M-component production rates Stage II A/B [35] Moderate diffuse disease
IgG value >7.0 g/dl 20 focal lesions
IgA value >5.0 g/dl Stage III A/B [35] Severe diffuse disease
Urine light chain M-component on
electrophoresis >12 g/24 h
Sub classification (either A or B) [35] A Serum creatinine <2.0 mg/dl
A: relatively normal renal function (serum creatinine value) <2.0 mg/dl No extramedullary disease (EMD)
B: abnormal renal function (serum creatinine value) >2.0 mg/dl [35] B Serum creatinine ≥2.0 mg/dl
Extramedullary disease (EMD)
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osteoporosis [7, 8].
However, radiography is more helpful in detecting
trabecular/cortical bone lesions while MRI is more sensi-
tive, particularly in the vertebral bone marrow, to show
diffuse or focal bone marrow involvement, which has not or
not yet caused destruction of mineralised bone.
Another disadvantage of radiographic technologies is
that history and activity status of myeloma cannot be
estimated [9].
A further disadvantage of radiography is that varied
positions required for radiography films are painful and
tiring for patients who are often elderly and disabled due to
previous pathological fractures.
Multidetector computed tomography
Multidetector computed tomography (MDCT) is a widely
employed alternative to conventional radiography and is
considered as the ideal tool for detection of early bone
destruction [9].
Extramedullary lesions can also be detected and the
diagnostic sensitivity of CT imaging is superior to that
of conventional radiography and reveals more lesions in
areas that cannot be accurately visualised by radiography
[10, 11].
Moreover, it has been shown that CT is superior to
conventional radiography in estimating instability of areas
with bone lesions and fracture risk, e.g. prior to vertebro-
plasty [12]. Unfortunately, the radiation dose used in CT is
much higher (up to 400 times, Table 2) than the dose used
in radiographic survey. Moreover, just as conventional
radiographic surveys, CT is non-specific for evaluation of
osteopaenia [13].
For staging of patients with multiple myeloma, evalua-
tion of the whole skeleton is critical. Therefore, whole-body
MDCT was introduced.
MDCT provides faster scanning time and higher z axis
resolution than single-slice helical CT, leading to high
quality real-time 3-D images [13]. Thus, MDCT is very
sensitive in detecting small osteolytic lesions (<5 mm),
especially in the spine [13] and leads to high-resolution
imaging of cortical and trabecular bone within an acquisi-
tion time of 1 min [5].
Another advantage is that, due to increased accuracy of
multiplanar acquisition technique, distinction of bony
structures and soft tissues is possible to a much higher
level avoiding artefacts such as shadows that could lead to
false-positive results [10].
Using MDCT, the effects of tumour infiltration can be
visualised. However, it takes some time before osteoclastic
activity of myeloma cells leads to bone destruction.
Therefore, MDCT will show no abnormalities in early
focal marrow infiltration [5].
In diffuse bone marrow infiltration, the false-negative
rate is relatively high. This may be due to the fact that
diffuse infiltration leads to interstitial infiltration of bone
marrow which is not necessarily associated with destruction
of trabecular or cortical bone [5]. One of the most important
drawbacks in applying whole-body MDCT is the high-
radiation dose in access of 35 mSv [10].
To overcome this problem, whole-body low-dose com-
puted tomography (LDCT) was introduced.
Whole-body low-dose MDCT
Whole-body LDCT operates at lower radiation doses and is
superior to skeletal X-ray in detecting osteolytic lesions
and in determining overall stage of multiple myeloma
(restaging) [10], and the level of diagnostic confidence is
much higher when interpreting whole-body LDCT (at
lower doses than previously reported) than conventional
radiography. In addition, further reductions in radiation
doses are feasible.
Furthermore, additional findings detectable on whole-
body LDCT, e.g. additional osteolytic lesions, emphysema,
lymphadenopathy or hepatosplenomegaly cannot be
detected on conventional skeletal survey [10].
Whole-body LDCT is superior to whole-body mag-
netic resonance imaging (WB-MRI) in detecting residual
osteolytic abnormalities which are mostly not seen on
WB-MRI.
The sharp algorithm used to optimise osseous structure
assessment implies that the diagnosis of visceral pathology
is limited but this problem could be overcome by the use of
a special soft tissue algorithm [10].
Furthermore, iodine-containing contrast agents, relatively
contraindicated for patients with Bence–Jones proteinuria
because of the risk of cast nephropathy and renal failure, are
not needed for skeletal CT [14].
Table 2 Comparison of typical doses from CT and conventional
X-ray examinations [34]
Diagnostic procedure Typical effective dose (mSv)
Conventional X-ray
Chest (single PA film) 0.02
Pelvis 0.7
Abdomen 1.0
Computed tomography
Chest 8
Pelvis 10
Abdomen 10
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Whole-body MRI
Using magnetic resonance imaging (MRI), bone marrow
involvement, loss of fatty bone marrow components and
replacement by pathologic cells can be evaluated [15].
Moreover, MRI has prognostic significance; the number
of lesions on MRI correlates very well with treatment
outcome and overall survival of patients with multiple
myeloma [16]. However, the pattern of marrow infiltration
(focal or diffuse) does not necessarily equate with a need
for immediate therapy.
Unfortunately, this technology also has some disadvan-
tages such as prolonged acquisition time (about 45 min),
high costs and limiting patient factors such as claustrophobia
or metal devices in their body [1, 9].
The difficulty of radiography to distinguish between
treated bone marrow lesions and viable neoplastic tissue
(active and fibrotic lesions) is encountered in MRI as well
[1, 17]. This results in limited capacity to monitor the
response to therapy because it takes 9–12 months for
lesions evident on MRI to resolve and be clearly indicative
of response [9].
Although bone marrow infiltration of ribs, spine (most
importantly), pelvis and sternum [7, 18] and extensive
disease [19] can be visualised and MRI is more sensitive
and specific than radiological skeletal surveys in detecting
disease [19], it is not able to explore specific bones [1, 18]
such as the skull, clavicle or ribs. These bones cannot be
investigated reliably because of respiratory movements or
because they could be too small to be located in one of the
MRI slices leading to false-negative results and under-
staging of multiple myeloma patients.
To overcome the disadvantages of a partial field of view,
whole-body MRI (WB-MRI) was introduced which pro-
vides several benefits.
With this technique, the patient’s whole body can be
scanned. Unfortunately, WB-MRI is not yet widely
employed and less available [1].
WB-MRI has been reported to be particularly useful in
early smouldering MM likely to be less FDG avid [10]a n di t
is most common to scan the spine and pelvis for screening
purposes [9] because of the more detailed assessment of
bone marrow infiltration pattern.
As compared to whole-body MDCT, WB-MRI has
superior sensitivity for both focal and diffuse pattern of
bone marrow involvement and will result in upstaging of
multiple myeloma. Moreover, the detection rate of exten-
sive disease and the rate of bone manifestations using WB-
MRI are higher than whole-body MDCT [5, 10].
WB-MRI also detects more lesions than whole-body
LDCT [10].
It has been recommended to apply WB-MRI in addition
to standard skeletal survey for several reasons [18]: First, it
allows detection of focal lesions before osteolysis can be
visualised on a bone survey. Second, detection and staging
of nonsecretory and macrofocal myeloma and detecting of
nonsecretory or macrofocal relapse are possible. Relapse on
MRI can be diagnosed when an increase in size/number of
focal lesions or development of abnormal diffuse bone
marrow becomes present [18].
Dynamic contrast-enhanced MRI
To detect and monitor changes in bone marrow microcir-
culation as a result of myeloma-induced angiogenesis and
blood vessel permeability, dynamic contrast-enhanced MRI
was introduced (DCE-MRI) [20].
This non-invasive technique allows evaluation of the
microcirculation in malignant tissues.
It has been reported that DCE-MRI-derived microcircu-
lation variable amplitude A is proportional to the relative
signal enhancement. This signal was significantly increased
in patients with multiple myeloma, correlated with osteolytic
bone involvement [20] and was identified as an adverse
prognostic variable for event-free survival in progressive
myeloma. A high amplitude A, thus an increased micro-
circulation, points towards a low event-free survival [20].
Amplitude A as an adverse prognostic variable showed a
trend for overall survival as well.
DCE-MRI also correlates with local complications and
degree of bone destruction in multiple myeloma [20].
The most important advantage of this technique is the
possibility to identify patients who could profit from
therapeutics targeting the microcirculation with antiangio-
genic drugs such as bevacizumab, a monoclonal antibody
inhibiting vascular endothelial growth factor (VEGF) [20].
Furthermore, it has been shown that DCE-MRI could
complement standard MRI and may be superior in deter-
mining disease activity and response to therapy [20, 21].
Besides many advantages of the described techniques,
determining history and activity status of bone lesions in
multiple myeloma cannot be assessed.
FDG-PET
Fluorodeoxyglucose is an analogue of glucose which is
labelled with the positron-emitting radionuclide
18F.
Fluorodeoxyglucose is taken up and phosphorylised by
metabolically active cells which do not further metabolise it
but store it after uptake. This results in an accumulation of
this molecule that can be visualised with PET.
Tumour cells can be imaged with this technique due to
their high metabolism rate and the resulting high glucose
1164 Ann Hematol (2009) 88:1161–1168demand. This allows tumour cells to be distinguished from
normal cells.
Conventional FDG-PET
One of the most important advantages of FDG-PET is the
ability to scan the whole body in reasonable time frame [9]
and in a single procedure [17].
Furthermore, FDG-PET can detect bone marrow/
myelomatous involvement with high sensitivity and speci-
ficity. FDG-PET can detect and distinguish between
intramedullary and extramedullary lesions in a single
examination in patients with multiple myeloma [17].
Unfortunately, very small lesions (subcentimeter size) may
not be detected as a certain minimum tumour burden is
required for delineation by FDG-PET [17].
It has been reported that FDG-PET for the assessment
of disease extent at the time of initial diagnosis resulted in
upstaging of disease and thus more aggressive therapy
[17].
The most significant advantageous feature of FDG-PET
is probably being a functional imaging technique by its
ability to distinguish between active myeloma (FDG-
positive) and monoclonal gammopathy of undetermined
significance (MGUS) or smouldering disease.
MGUS is defined by the presence of a serum mono-
clonal (M) protein <3 g/dL, bone marrow plasma cells
<10%, and absence of anaemia, hypocalcaemia, lytic bone
lesions, or renal failure attributable to the plasma cell
proliferative disorder [22].
Smouldering disease is defined by serum M protein
≥3 g/dL or bone marrow plasma cells ≥10%, plus absence
of anaemia, hypocalcaemia, lytic bone lesions, or renal
failure attributable to the plasma cell proliferative disorder
[22].
Usually, MGUS and low-level smouldering disease are
negative on FDG-PET [9] with MGUS showing neither
diffuse marrow uptake nor areas of focal disease in marrow
sites [23].
Active myeloma is FDG-positive for focal and diffuse
abnormalities and FDG uptake decreases rapidly (within
hours) after effective therapy. Persistent FDG-PET positiv-
ity correlates with earlier relapse [9].
As FDG-PET also detects inflammatory and infectious
complications, it can be useful for diagnosis of complica-
tions of therapy, such as vascular infections as septic
thrombophlebitis, infections of implantable catheters and
severe neutropaenia which can lead to modifications of the
therapeutic strategy [24].
However, it has to be taken into account that infection
and inflammation (also after radiotherapy or surgery) may
result in false-positive interpretation for active multiple
myeloma [17].
FDG-PET combined with CT
To overcome the low spatial resolution of FDG-PET,
integrated FDG-PET/CT has become the standard method-
ology. FDG-PET/CT combines the high contrast resolution
(sensitivity) of PET with high spatial resolution (anatomy)
of CT, which is more sensitive than whole-body radiogra-
phy for detection of small lytic bone lesions and has similar
sensitivity as MRI in detecting diffuse disease in spine and
pelvis. Furthermore, FDG-PET combined with CT per-
formed better than
99mTc-MIBI and MRI in detection of
focal lesions [25]. However, an infiltrative pattern in the
spine can be depicted more adequately with MRI than with
FDG-PET/CT [1].
It has been reported that FDG-PET/CT can significantly
contribute to an accurate whole-body evaluation of multiple
myeloma patients while MRI should be used especially for
evaluation of bone marrow involvement [25], because it
allows visualisation of the bone content with a high spatial
resolution [25, 26]
Durie et al. [9] conclude in their paper that FDG-PET
combined with CT scanning would provide the ideal
screening technology for multiple myeloma since FDG-
PET uptake indicates active myeloma and CT shows bone
destruction [9, 27].
99mTc-MIBI
99mTc-labelled hexakis-2-methoxyisobutylisonitrile is a
radiopharmaceutical which accumulates in tissues with
high cellular density and mitochondrial activation as it can
be found in malignant tissues.
99mTc-MIBI imaging reflects
myeloma disease activity in bone marrow with very high
sensitivity and specificity [28, 29]. Additionally, bone
marrow biopsy results linearly correlate with bone marrow
uptake of
99mTc-MIBI and
99mTc-MIBI was reported to be
localised inside the plasma cells infiltrating the bone
marrow [8].
In MGUS,
99mTc-MIBI is always negative [8] so it could
be useful in discrimination between MGUS and multiple
myeloma.
Using
99mTc-MIBI, it is possible to scan soft and skeletal
lesions and the overall sensitivity is approximately 92% and
it specificity is 96% [30].
99mTc-MIBI is superior compared
with FDG-PET/CT for the visualisation of diffuse disease
and despite its limited capacity in detecting focal lesions
this technique may be an alternative option when PET is
not available.
In comparison to MRI, it has been found that
99mTc-
MIBI underestimates the extent of bone marrow infiltra-
tion in the spine, especially in patients with low disease
stage [31].
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Because early myeloma may reveal no abnormalities on
conventional radiography, Durie et al. [9] introduced an
update of their original staging system published in 2005.
The new system, named Durie/Salmon PLUS staging
system, integrates new imaging techniques into anatomic
and functional myeloma staging (Table 1).
The new system overcomes two limitations: on the one
hand, the classification of early disease detected only by
PET/CT and/or MRI becomes better since patients with
definite active myeloma are distinguished from those with
MGUS or smouldering disease and on the other hand, the
discrimination of patients with stage II and III disease will
be improved.
In clinical studies, the CRAB criteria are used to
establish multiple myeloma related organ dysfunction:
hypercalcaemia, renal disease, anaemia and osteolytic
bone lesions. In these criteria multiple osteolytic bone
lesions is an item, as well as osteoporosis or a solitary
plasmocytoma given more than 30% bone marrow plasma
cells.
New developments
Although many new technologies were introduced during
the past decennia, all have special impediments.
A relatively new technology is diffusion-weighted whole-
body imaging with background body signal suppression
(DWIBS). With this technique, altered diffusion in cells and
tissues can be detected as it may appear in malignant
tumours bearing high cellular density with more cellular
membranes per volume unit, impeding the mobility of
water molecules and restricting diffusion [32].
On the other hand, diffusion may be increased in tumours
as well, due to necrotic loss of cell membrane integrity.
There are several potential applications of DWIBS in
oncology, for instance in staging, monitoring response to
therapy or detection of tumour persistence or recurrence.
Even though these features could complement conventional
technologies, much research is still necessary.
Another imaging technique for multiple myeloma is
the recently developed PET tracer 3′-fluoro-3′-deoxy-L-
thymidine (
18F-FLT).
18F-FLT is taken up into cells in
relation to the rate of DNA synthesis and with higher
proliferation rates as it is common in many cancers,
18F-
FLT increases in the cells [33]. Therefore,
18F-FLT PET
might visualise the high cycling activity of haemato-
poietic cells in the bone marrow compartment and may
be helpful to distinguish separate haematologic disorders
[33]( T a b l e3).
Discussion
Currently, the baseline diagnostic evaluation to detect
osteolytic bone lesions comprises conventional radiogra-
phy. In case of negative results while symptoms of the
disease are present, CT or MRI is usually performed.
Table 3 Overview of the different technologies
X-ray CT MDCT LDCT MRI WB-MRI DCE-MRI PET/CT Tc-MIBI
Costs (− low, + high) − ++ / − +/− ++ ++ ++ +++ ++
Radiation (mSv) + ++ +++ ++ −− − + −
Acquisition time (− low, + high) − + −− ++ +++ ++ ++ ++
Patient experience +++ +/− ++/− ++/−− − − − −
Sensitivity +/− + ++ + ++ +++ + +++ ++
Availability +++ ++ + + + −− + −
Spatial resolution + ++ ++ ++ ++ +++ + ++ +
Understaging (− low risk, + high risk) + + + + +/−− − − +/−
Early diagnosis −− − − + + + +++ ++
Bone marrow −− +/− − ++ ++ ++ + +
Osteolytic lesions +/− ++ ++ ++ + + + ++ −
Age and activity status of MM −− − − − − +/− ++ +
Response to therapy −− − − +/− +/− ++/− ++ +
Bone marrow microcirculation −− − − − − + −−
Subcentimeter lesions +/− ++ + < 5 m m + + + + +
Separation MGUS and MM −− − − ++ +
Focal lesions + + + + ++ ++ − +++ +/++
Diffuse lesions + + + + ++ ++ − ++ +++
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radiographic surveys have profound disadvantages such as
relatively high false-negative rates and lack of bone marrow
evaluation which make this technology less suitable for
early diagnosing/staging/evaluating multiple myeloma.
CT overcomes problems as low anatomic resolution
and the newly developed whole-body technology allows
examination of the whole body to diagnose spread of the
disease in the periphery. Nonetheless, converse to conven-
tional radiography, the radiation dose is much higher.
Therefore, whole-body LDCT was introduced. Despite
lower radiation doses, given a high-enough resolution of
the CT scan the sensitivity for detecting osteolytic foci and
determining overall stage is still much higher than in simple
radiographic technologies [10].
In our view, the most sensitive technique to evaluate
osteolytic bone lesions in multiple myeloma is PET/LDCT.
The addition of PET to the low-dose CT will enhance the
sensitivity for detection of rib lesions and extramedullary
lesions. Moreover, as compared to MRI and
99mTc-MIBI,
hybrid FDG-PET/LDCT performed better in detection of
focal lesions. Furthermore, FDG-PET offers great opportu-
nities because of the capacity to differentiate between bone
marrow lesions and viable neoplastic tissue, due to the
ability to visualise highly energy-consuming cells such as
tumour cells.
Thus, introduction of these hybrid FDG-PET/LDCT
scanners facilitates the determination of the accurate
anatomical position of active disease as detected by PET
with an acceptable radiation dose.
Because it has been shown that MRI is more sensitive
than FDG-PET/LDCT in detecting infiltrative pattern in
the spine [1], careful evaluation of multiple myeloma
bone disease can include WB-MRI in case the patient has
complaint with a negative FDG-PET/LDCT. However,
whereas WB-MRI is very sensitive in detecting bone
marrow involvement, the major reason to treat patients
with myeloma is osteolytic disease, which is not detected
by MRI.
Also regarding to follow-up, PET/LDCT is the most
sensitive technique to evaluate result of treatment. In that
respect, it is more sensitive than MRI to differentiate
between treated bone marrow lesions and viable neoplastic
tissues.
We conclude that FDG-PET/LDCT can replace the
golden standard, conventional radiography. We have to
realise that due to the higher sensitivity, patients will be
upstaged and treatment in this group of patients will start in
an earlier phase of the disease. However, from a patient’s
point of view and given the more effective treatment
combinations available nowadays with more complete
remissions in first-line treatment, skeletal damage can be
prevented at least in some of the patients.
In clinical studies, it may be considered to perform
conventional radiography next to FDG-PET/LDCT in order
to compare the treatment results with historical data.
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